Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocorrx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocorrx's position in the market.
BioCorRx Inc. (OTCQB: BICX), a developer of innovative substance abuse treatment programs, provided a business update for Q2 2024. Key highlights include:
1. Expansion of intellectual property portfolio with a new international patent from Israel for weight loss treatment using naltrexone implants.
2. A new USPTO patent for a novel compound potentially reducing opioid withdrawal symptoms.
3. A $11 million grant from NIDA for developing BICX104, a long-duration naltrexone implant for methamphetamine use disorder (MUD).
The company remains focused on addressing global unmet medical needs in obesity and substance abuse, with ongoing progress in development efforts and strategic priorities aimed at creating shareholder value.
FAQ
What is the current stock price of Biocorrx (BICX)?
What is the market cap of Biocorrx (BICX)?
